Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of gantenerumab in early Alzheimer's disease
NL-OMON50345Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gantenerumab in Alzheimer's disease (AD), sponsored by Roche. Primary endpoints: Change from baseline in CDR-SOB and Long-term safety and tolerability in open-label extension. Started Oct 2018; status: active, not recruiting.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON50345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50345.